- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00187343
A Clinical Trial to Reduce Skin Burn Induced by Breast Radiotherapy Using Intensity Modulated Radiation Therapy (IMRT)
A Phase III Study of Adjuvant Radiation Therapy in Early Breast Cancer Comparing the Use of Breast Intensity Modulated Radiation Therapy (IMRT) to Conventional Wedge Technique
Visão geral do estudo
Descrição detalhada
Description of the Problem:
The majority of breast cancer patients are treated with breast-conserving surgery followed by radiotherapy, giving loco-regional control rates similar to mastectomy. Currently, the "standard" breast radiotherapy technique includes treatment of the entire breast with a tangential opposed pair of photon beams. The standard technique leads to significant acute skin toxicity, ranging from breast erythema to moist desquamation, in approximately 40% of patients. This toxicity may lead to interruptions in treatment delivery; may increase the risk of developing late skin toxicity including telangiectasia, skin fibrosis and chronic breast pain; and may also be associated with a significant decrease in health-related quality of life (HRQOL). Published data from dosimetric studies suggest that dose variations in excess of 10% within the breast may be the most important predictor of acute radiation-induced skin toxicity (RR = 9.7), and that dose toxicity occurs more frequently in the inframamary fold. A study performed at TSRCC shows that intensity modulated radiotherapy (IMRT) allows for significant improvements in dose homogeneity within the breast compared to standard breast radiotherapy techniques. Furthermore, the hot spot over 10% seen in the inframamary fold for patient with large breast volume is removed.
Objectives:
- To determine if the occurence of acute skin toxicity in women receiving adjuvant breast radiation with IMRT is less frequent compared to women treated with conventional technique.
- To determine if the HRQOL scores, and specifically breast module subscale scores, in women receiving adjuvant breast radiation with IMRT is better than HRQOL scores in women receiving conventional technique.
- To perform a comparison of costs in the delivery of breast radiotherapy using IMRT to conventional technique.
- To determine if an increased acute skin toxicity translates into an increased late skin toxicity.
- Hypothesis:
We hypothesize that women receiving adjuvant breast radiation with IMRT will have significantly less acute skin toxicity and improved HRQOL compared to women treated with conventional techniques. We also hypothesize that there would not be increased cost related to IMRT compared to conventional technique.
Research plan: A Phase III randomised controled trial is planned, with blocked stratification on breast size and boost delivery. Eligible women include those who have been referred to TSRCC following breast-conserving surgery. They will be randomized to receive either a conventional technique treatment, either breast IMRT. Acute skin toxicity will be assessed weekly during radiotherapy and up to one month following completion of radiotherapy using the previously validated RTOG acute skin toxicity scale. The occurence, duration and intensity of acute skin toxicity will be compared. HRQOL will be assessed during and after irradiation, using validated EORTC instruments (EORTC QLQ-C30 and QLQ-BR23). 340 patients will be accrued in order to detect a 15% reduction in the ocurence of acute skin toxicity with IMRT using an a=0.05, b=0.80.
Tipo de estudo
Inscrição
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
British Columbia
-
Victoria, British Columbia, Canadá, V8R6V5
- BC Cancer Agency-Vancouver Island Centre
-
-
Ontario
-
Toronto, Ontario, Canadá, M4N3M5
- Sunnybrook and Women's College Health Sciences Centre
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- A confirmed histological diagnosis of breast carcinoma or DCIS;
- Treated by breast conserving surgery;
- Adjuvant radiation to the breast only (less than 3 positive lymph nodes);
- Having a ECOG performance status of 0 or 1.
- Having signed an informed consent.
Exclusion Criteria:
- Patients treated by mastectomy;
- Bilateral breast cancer;
- Having an unhealed surgical scar (skin not closed and/or infection);
- Having had prior radiation to the same breast;
- Having active connective tissue disorder;
- Patient being pregnant.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
---|
Maximum skin toxicity measured weekly during the tratment and bi-weekly up to one month after the end of the treatment and complete resolution of skin reaction using the NCI common toxicity criteria version 3.0 scale
|
Medidas de resultados secundários
Medida de resultado |
---|
Breast localisation of maximum acute skin toxicity;
|
Time of onset of acute skin toxicity;
|
Pain assessment;
|
Duration of symptoms;
|
Factors associated with acute skin reactions;
|
HRQOL;
|
Drug prescription for skin care.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jean-Philippe PIGNOL, MD, PhD, Sunnybrook Health Sciences Centre
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- BreastIMRT
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Breast IMRT
-
Memorial Sloan Kettering Cancer CenterAtivo, não recrutando
-
Medical University of GrazConcluídoQualidade de vida | Satisfação, Paciente | Complicações Pós-Operatórias/PerioperatóriasÁustria
-
Thurgau Breast CenterRecrutamento
-
Royal Marsden NHS Foundation TrustDesconhecidoCâncer de mamaReino Unido
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoNódulo de mama sintomáticoEstados Unidos
-
Memorial Sloan Kettering Cancer CenterAtivo, não recrutandoCâncer de mamaEstados Unidos
-
Cancer Institute and Hospital, Chinese Academy...DesconhecidoCâncer de Pulmão de Pequenas CélulasChina
-
National Cancer Institute, EgyptAtivo, não recrutando
-
Sun Yat-sen UniversityAtivo, não recrutandoQualidade de vida | Mortalidade | Neoplasias Nasofaríngeas | ComplicaçõesChina
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyConcluídoDisfunção sexual | Câncer de próstata | Toxicidade de radiação | Efeitos psicossociais do câncer e seu tratamentoEstados Unidos, Canadá